Bivalirudin interactions
Full monograph for BivalirudinCheck it against another medicine
Medicines
94 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Allium cepa + Heparin + Allantoin | Major | Synergy | The concomitant administration of bivalirudin and other anticoagulants may increase the risk of bleeding complications due to additive or synergistic effects… | 38 sources — open the full entry |
| Alteplase | Major | Synergy | The concomitant administration of thrombin inhibitors and thrombolytic agents may increase the risk of bleeding complications. Intracranial bleeding has been… | 1 sources — open the full entry |
| Apixaban | Major | Synergy | Concomitant use of apixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Betrixaban | Major | Synergy | Concomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Cabozantinib | Major | Synergy | Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 39 sources — open the full entry |
| Cilostazol | Major | Synergy | Concomitant use of thrombin inhibitors and antiplatelet agents may increase the risk of bleeding complications due to additive or synergistic effects on the… | 3 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Major | Synergy | Drugs that can affect hemostasis such as glycoprotein IIb/IIIa inhibitors, thienopyridine antiplatelet agents, unfractionated and low molecular weight… | 3 sources — open the full entry |
| Dalteparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Dasatinib | Major | Synergy | Coadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 5 sources — open the full entry |
| Deferasirox | Major | Synergy | Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of… | 3 sources — open the full entry |
| Enoxaparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Fondaparinux Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Heparin Sodium | Major | Synergy | The concomitant administration of bivalirudin and other anticoagulants may increase the risk of bleeding complications due to additive or synergistic effects… | 38 sources — open the full entry |
| Ibrutinib | Major | Synergy | Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 6 sources — open the full entry |
| Mifepristone | Major | Synergy | Concomitant use of anticoagulants may exacerbate mifepristone-induced vaginal bleeding in women. Prolonged, potentially heavy bleeding lasting approximately 9… | 4 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Synergy | Concomitant use of anticoagulants may exacerbate mifepristone-induced vaginal bleeding in women. Prolonged, potentially heavy bleeding lasting approximately 9… | 4 sources — open the full entry |
| Ponatinib Hydrochloride | Major | Synergy | Coadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 3 sources — open the full entry |
| Prasugrel Hydrochloride | Major | Synergy | Concomitant use of prasugrel with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents… | 2 sources — open the full entry |
| Ramucirumab | Major | Synergy | Coadministration of ramucirumab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Ramucirumab… | 2 sources — open the full entry |
| Regorafenib Monohydrate | Major | Synergy | Coadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 5 sources — open the full entry |
| Rivaroxaban | Major | Synergy | Concomitant use of rivaroxaban with other anticoagulants may increase the risk of bleeding. In patients receiving neuraxial anesthesia or spinal puncture, the… | 1 sources — open the full entry |
| Streptokinase | Major | Synergy | The concomitant administration of thrombin inhibitors and thrombolytic agents may increase the risk of bleeding complications. Intracranial bleeding has been… | 1 sources — open the full entry |
| Tenecteplase | Major | Synergy | The concomitant administration of thrombin inhibitors and thrombolytic agents may increase the risk of bleeding complications. Intracranial bleeding has been… | 1 sources — open the full entry |
| Trastuzumab Emtansine | Major | Synergy | Coadministration of trastuzumab emtansine with anticoagulant or antiplatelet drugs may potentiate the risk of hemorrhagic events associated with these drugs… | 40 sources — open the full entry |
| Warfarin Sodium | Major | Synergy | The concomitant administration of bivalirudin and other anticoagulants may increase the risk of bleeding complications due to additive or synergistic effects… | 38 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. | 8 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Synergy | Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and… | 20 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. | 8 sources — open the full entry |
| Bismuth Subsalicylate | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K… | 8 sources — open the full entry |
| Bromfenac Sodium | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Cetalkonium Chloride + Choline Salicylate | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K… | 8 sources — open the full entry |
| Citalopram Hydrobromide | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
| Clobetasol Propionate + Salicylic Acid | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. | 8 sources — open the full entry |
| Clomipramine Hydrochloride | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
| Clopidogrel + Aspirin | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Clopidogrel Bisulphate | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Coal Tar + Precipitated Sulphur + Salicylic Acid | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. | 8 sources — open the full entry |
| Desvenlafaxine Succinate | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
| Dexibuprofen | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Dexketoprofen | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Diclofenac Potassium | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Diclofenac Sodium | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Diclofenac Sodium (Ophthalmic) | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Diclofenac Sodium + Methyl Salicylate + Linseed Oil + Menthol | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Diclofenac Sodium + Misoprostol | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
| Dipyridamole | Moderate | Synergy | The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the… | 1 sources — open the full entry |
Conditions
Conditions in which Bivalirudin needs care, as documented in this source.
Hemorrhage
MajorThe use of thrombin inhibitors is contraindicated in the presence of active major bleeding. Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.
2 sources
- "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim (2010):
- "Product Information. Bivalirudin (bivalirudin)." Fresenius Kabi USA, LLC (2016):
Kidney Diseases
ModerateClinical studies showed that the clearance of bivalirudin is reduced approximately 20% with moderate and severe renal impairment and is reduced about 80% in dialysis-dependent patients. The infusion dose of bivalirudin may need to be reduced, and anticoagulant status monitored in patients with renal impairment.
1 source
- "Product Information. Bivalirudin (bivalirudin)." Fresenius Kabi USA, LLC (2016):